107 related articles for article (PubMed ID: 19098386)
41. Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice.
Yan Y; Yamada K; Mizoguchi H; Noda Y; Nagai T; Nitta A; Nabeshima T
Neuroscience; 2007 Apr; 146(1):50-9. PubMed ID: 17317018
[TBL] [Abstract][Full Text] [Related]
42. Role of dopamine in the behavioural actions of nicotine related to addiction.
Di Chiara G
Eur J Pharmacol; 2000 Mar; 393(1-3):295-314. PubMed ID: 10771025
[TBL] [Abstract][Full Text] [Related]
43. Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens.
Sellings LH; Baharnouri G; McQuade LE; Clarke PB
Eur J Neurosci; 2008 Jul; 28(2):342-52. PubMed ID: 18702705
[TBL] [Abstract][Full Text] [Related]
44. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
45. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area.
Laviolette SR; van der Kooy D
Mol Psychiatry; 2003 Jan; 8(1):50-9, 9. PubMed ID: 12556908
[TBL] [Abstract][Full Text] [Related]
46. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.
Zhang G; Kernan KA; Collins SJ; Cai X; López-Guisa JM; Degen JL; Shvil Y; Eddy AA
J Am Soc Nephrol; 2007 Mar; 18(3):846-59. PubMed ID: 17267741
[TBL] [Abstract][Full Text] [Related]
47. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
[TBL] [Abstract][Full Text] [Related]
48. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
Van Nostrand WE; Porter M
Biochemistry; 1999 Aug; 38(35):11570-6. PubMed ID: 10471309
[TBL] [Abstract][Full Text] [Related]
49. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
50. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.
Jackson A; Bagdas D; Muldoon PP; Lichtman AH; Carroll FI; Greenwald M; Miles MF; Damaj MI
Neuropharmacology; 2017 May; 118():38-45. PubMed ID: 28279662
[TBL] [Abstract][Full Text] [Related]
51. Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism.
Welling TH; Huber TS; Messina LM; Stanley JC
J Surg Res; 1996 Nov; 66(1):36-42. PubMed ID: 8954829
[TBL] [Abstract][Full Text] [Related]
52. Myosin as cofactor and substrate in fibrinolysis.
Machovich R; Ajtai K; Kolev K; Owen WG
FEBS Lett; 1997 Apr; 407(1):93-6. PubMed ID: 9141488
[TBL] [Abstract][Full Text] [Related]
53. uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis.
Kanno Y; Ishisaki A; Kawashita E; Kuretake H; Ikeda K; Matsuo O
Int J Biol Sci; 2016; 12(1):63-71. PubMed ID: 26722218
[TBL] [Abstract][Full Text] [Related]
54. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Baricos WH; Reed JC; Cortez SL
Exp Biol Med (Maywood); 2003 Oct; 228(9):1018-22. PubMed ID: 14530509
[TBL] [Abstract][Full Text] [Related]
55. Proteolysis of highly polysialylated NCAM by the tissue plasminogen activator-plasmin system in rats.
Endo A; Nagai N; Urano T; Ihara H; Takada Y; Hashimoto K; Takada A
Neurosci Lett; 1998 Apr; 246(1):37-40. PubMed ID: 9622202
[TBL] [Abstract][Full Text] [Related]
56. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence.
Balfour DJ; Wright AE; Benwell ME; Birrell CE
Behav Brain Res; 2000 Aug; 113(1-2):73-83. PubMed ID: 10942034
[TBL] [Abstract][Full Text] [Related]
57. Nicotine-conditioned single-trial place preference: selective role of nucleus accumbens shell dopamine D1 receptors in acquisition.
Spina L; Fenu S; Longoni R; Rivas E; Di Chiara G
Psychopharmacology (Berl); 2006 Mar; 184(3-4):447-55. PubMed ID: 16341849
[TBL] [Abstract][Full Text] [Related]
58. Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: aggravation and therapeutic potential.
Gur-Wahnon D; Mizrachi T; Wald-Altman S; Al-Roof Higazi A; Brenner T
J Autoimmun; 2014 Aug; 52():36-43. PubMed ID: 24423642
[TBL] [Abstract][Full Text] [Related]
59. Nicotine and ethanol activate protein kinase A synergistically via G(i) betagamma subunits in nucleus accumbens/ventral tegmental cocultures: the role of dopamine D(1)/D(2) and adenosine A(2A) receptors.
Inoue Y; Yao L; Hopf FW; Fan P; Jiang Z; Bonci A; Diamond I
J Pharmacol Exp Ther; 2007 Jul; 322(1):23-9. PubMed ID: 17468300
[TBL] [Abstract][Full Text] [Related]
60. Nicotine-induced molecular alterations are modulated by GABA
Varani AP; Pedrón VT; Aon AJ; Höcht C; Acosta GB; Bettler B; Balerio GN
Addict Biol; 2018 Jan; 23(1):230-246. PubMed ID: 28419642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
